ERBB2 and neoplasm: The use of trastuzumab, a humanized monoclonal antibody that binds the extracellular, juxtamembranal domain of HER2/neu, in combination with multiple chemotherapeutic agents showed additive and synergistic effects, possibly by increasing susceptibility to chemotherapy-induced apoptosis and slowing down tumor growth and damage repair [4].